AUTHORS
Ayman Youssef, MD, MSc, Pedro Ortiz, MD2, James Muldowney, MD3, Kishan Tarpara, DO4, Ralf Habermann, MD5, Amanda Peltier, MD6, Daniel Carranza, MD7, Morgane Giesecke, APRN8, Yuliya Vance, APRN9, Italo Biaggioni, MD10, Cyndya Shibao, MD11, Adetola Kassim Kassim, MD, MS12
AFFILIATIONS
1 Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 Vanderbilt University Medical Center, Nashville, Tennessee, United States
3 Vanderbilt University Medical Center, Nashville, Tennessee, United States
4 Vanderbilt University Medical Center, Nashville, Tennessee, United States, Vanderbilt University Medical Center, Nashville, United States
5 Vanderbilt University Medical Center, Nashville, Tennessee, United States
6 Vanderbilt University Medical Center, Nashville, Tennessee, United States, Vanderbilt University Medical Center, Nashville, United States
7 Vanderbilt University Medical Center, Nashville, Tennessee, United States
8 Vanderbilt University Medical Center, Nashville, Tennessee, United States
9 Vanderbilt University Medical Center, Nashville, Tennessee, United States
10 Vanderbilt University Medical Center, Nashville, Tennessee, United States
11 Vanderbilt University Medical Center, Nashville, Tennessee, United States
12 Vanderbilt University Medical Center, Nashville, Tennessee, United States
ABSTRACT
Background
Orthostatic hypotension (OH) is a common manifestation of autonomic dysfunction and is linked to increased morbidity and mortality in the general population. Although autonomic dysfunction is increasingly recognized in patients with cancer, its prognostic significance in hematologic malignancies remains poorly defined. We hypothesized that OH and abnormalities on objective autonomic function testing (AFT) identify patients with hematologic malignancies at increased risk of mortality.
Aims
To evaluate the association of OH and objective autonomic dysfunction with overall survival in patients with hematologic malignancies.
Methods
We conducted a retrospective propensity score-matched cohort study of patients with hematologic malignancies who underwent comprehensive autonomic function testing (AFT) at a tertiary referral center including 10-minute tilt table, controlled breathing, and Valsalva maneuver tests. We excluded patients with pre-existing autonomic dysfunction and those with light chain (AL) amyloidosis either existing alone or concurrent with multiple myeloma. Propensity scores were estimated using age, sex, hematologic malignancy subtype, disease stage, number of prior treatment lines, baseline comorbidities, and treatment-related toxicities, followed by 1:1 nearest-neighbor matching without replacement. Standardized mean difference (SMD) < 0.10 was used to indicate adequate balance between both groups. Overall survival was assessed using Kaplan-Meier analysis and compared using the log-rank test. Cox proportional hazards regression was used to identify independent predictors of mortality.
Results
After propensity score matching, 115 patients were included (58 with OH and 57 without OH). Mean age was 68.72 ± 11.6 and 67.6 ± 9 years, males were 41 (70.7%) and 40 (70.2%), and females were 17 (14.8%) and 17 (29.8%) in patients with OH and without OH respectively. B-cell non-Hodgkin lymphoma (26 (44.8%) in OH vs 25 (43.9%) in non-OH) was the most common diagnosis, followed by multiple myeloma (15 (25.9%) in OH vs 15 (26.3%) in non-OH), myeloproliferative neoplasms (7 (12.1%) in OH vs 7 (12.3%) in non-OH), myelodysplastic syndromes (5 (8.6%) in OH vs 5 (8.8%) in non-OH), and acute leukemias (5 (8.6%) vs 5 (8.8%) in non-OH). During a median follow-up of 57 months, mortality occurred in 17 of 58 patients (29.3%) with OH compared with 9 of 57 patients (15.8%) without OH. Kaplan-Meier analysis showed significantly inferior overall survival among patients with OH (5-year overall survival 70.7% vs. 84.2%, log-rank P=0.028). Patients with adverse outcomes exhibited significantly more severe autonomic dysfunction, characterized by greater orthostatic systolic blood pressure (SBP) reduction, impaired sympathetic adrenergic function during the Valsalva maneuver, prolonged Valsalva pressure recovery time, and impaired phase IV overshoot. In Cox regression analysis, orthostatic SBP reduction >40 mmHg was the strongest predictor of mortality (adjusted HR 2.46, 95% CI 1.43–4.24; P=0.001), followed by Valsalva pressure recovery time >10 seconds (adjusted HR 2.27, 95% CI 1.33–3.87; P=0.002), absence of phase IV Valsalva overshoot (adjusted HR 2.04, 95% CI 1.19–3.49; P=0.011), and supine hypertension (adjusted HR 1.71, 95% CI 1.01–2.90; P=0.047). Severe autonomic failure was more strongly associated with mortality in B-cell non-Hodgkin lymphoma (adjusted HR, 3.8; 95% CI, 1.7–8.6) than in other hematologic malignancy subtypes (adjusted HR, 1.4; 95% CI, 0.7–2.9; P for interaction=.03).
Conclusions
In this propensity score-matched cohort, OH was associated with significantly reduced overall survival in patients with hematologic malignancies. Objective markers of severe autonomic failure on AFT, including marked orthostatic SBP reduction and impaired sympathetic adrenergic function, identified patients at particularly high risk of mortality, with the strongest adverse prognostic association observed in those with B-cell non-Hodgkin lymphoma. These findings suggest that comprehensive AFT provides clinically meaningful prognostic information beyond conventional oncologic risk factors and may improve risk stratification in patients with hematologic malignancies.
DISCLOSURES
Ayman Youssef, MD, MSc: No relevant conflicts of interest to declare.